What makes a peptide age
A peptide chain isn't an eternal structure. Manning's classic review lists the main degradation routes: hydrolysis of bonds, deamidation of particular residues, oxidation of sensitive side chains — methionine, cysteine, tryptophan — plus physical processes like aggregation. Every route accelerates with heat; many with moisture and light.
That's the whole point of lyophilisation: remove the water and you switch off hydrolysis while slowing the rest of the chemistry. Dry powder in a sealed vial is the most stable form a peptide can live in. More in our article on lyophilisation.
Temperature, moisture, light — one at a time
Temperature is the universal accelerator: chemistry's rough rule is that reaction rates multiply with every ten degrees. Hence cool or cold storage of dry material as standard lab practice, with freezers for long horizons.
Moisture is sneakier: lyophilisate is hygroscopic and pulls water from the air eagerly. Open a cold vial in a warm room and you've collected condensation inside it. That's why vials are allowed to warm to room temperature before opening, and kept tightly closed — often with desiccant — in storage. Light adds photo-oxidation of sensitive residues; opaque packaging and a dark shelf close that question.
What this means in practice
For a buyer of research material the picture is simple: sealed vial, cold, dark, minimal warm-cool cycles. In solution everything changes for the worse — a dissolved peptide lives its own, much shorter life, and we have a separate article about that.
One last piece of honesty: specific stability timelines are a property of the specific molecule, confirmed only by analytics over time — not by generic claims. The principles above are chemistry, the same for everyone; the numbers for a batch are a question for that batch's documentation.
References
- Stability of Protein Pharmaceuticals: An Update — Pharmaceutical Research, 27(4), 544–575 (PMID 20143256; DOI 10.1007/s11095-009-0045-6), 2010.
- Instability, stabilization, and formulation of liquid protein pharmaceuticals — International Journal of Pharmaceutics, 185(2), 129–188 (DOI 10.1016/S0378-5173(99)00152-0), 1999.
